A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Status
Active
Cancer Type
Non-Hodgkin Lymphoma
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01204164
Protocol IDs
TG02-101 (primary)
Study Sponsor
Tragara Pharmaceuticals, Incorporated

Summary

This is a multicenter, open-label, dose escalation study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with different types of hematological malignancy.

Treatment Sites in Georgia


Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Study Coordinator:
Beverly Bryan
404-778-4994

Doctors:

Martha L. Arellano MD
Leonard T. Heffner Jr., MD
H. Jean Khoury MD, FACP